Sorin Group has completed the sale of Angel Whole Blood Separation System (Angel) and activAT Autologous Thrombin Processing Kit (activAT) product lines to Cytomedix for $7m in cash paid in installments over two and a half years.
Sorin Group said that the Angel product line consists of a blood processing device and disposable products used for separation of whole blood into red cells, platelet poor plasma and platelet rich plasma (PRP). And the activAT is designed to produce autologous thrombin serum from platelet poor plasma, providing a completely autologous, safe alternative to bovine-derived products.
Sorin Group also said that together the products had sales of approximately $5m in 2009.
Michel Darnaud, president of cardiopulmonary business unit, said: “We are pleased to enter into an agreement to sell these non-core assets to Cytomedix, and we count on Cytomedix to maintain the same high level of customer service, support and product excellence that our customers have come to expect from Sorin.”
Sorin Group is a medical device company and a provider in the treatment of cardiovascular diseases. The company develops, manufactures and markets medical technologies for cardiac surgery and for the treatment of cardiac rhythm disorders.
Cytomedix is a developer of biologically active regenerative therapies for wound care, inflammation and angiogenesis.